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ABSTRACT
ANALYSIS OF ESTROGEN AND PROGESTERONE BINDING
SITES IN CYTOSOL AND NUCLEI OF 7,12-DIMETHYBENZ(A)
ANTHRACENE-INDUCED RAT MAMMARY CARCINOMA:
HORMONE-DEPENDENT VS HORMONE
INDEPENDENT TUMOR POPULATIONS
Danny Michael Burns, M. S.
Morehead State University, 1983
The steroid hormones estrogen and progesterone
are involved in the growth and functions of. the normal
mammary gland, and many mammary tumors retain their
dependence on those hormones.

Steroids exert their

influence through binding to cytoplasmic receptor
proteins which act in the nucleus after binding steroid
molecules.

The presence or absence of steroid re-

ceptors may thus be an indicator of the retention or
loss of endocrine regulation.

In this study, mammary

carcinomas were induced in female Sprague-Dawley rats by
a single feeding of the chemical carcinogen 7,12dimethylbenz(a) anthracene.

Animals with tumors were

subjected to bilateral oophorectomy and tumors were
grouped according to response.

Tumors which regressed

completely were termed hormone-dependent, and those
which continued to grow were termed hormone-independent.
Tumors were analyzed for estrogen and progesterone
binding sites, both cytoplasmic and nuclear, and the
iii

hormone-dependent and hormone-independent groups were
compared based upon the presence or absence of steroid
receptors, distribution of receptors in cytosol and
nuclear compartments, binding site concentrations, and
dissociation constants of ligand-receptor complexes.
There was a positive correlation between estrogen
receptor positivity and tumor regression in response to
oophorectomy.

While the presence or absence of pro-

gesterone receptor alone was not predictive of response
to oophorectomy, the presence of progesterone receptor
when estrogen receptor was also present improved the
correlation.

Mean binding site concentrations for both

steroids were higher in the hormone-dependent group.
Analysis of dissociation constants indicated high
affinity binding sites for both steroids with no
significant differences between groups.
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INTRODUCTION
Much of our understanding of steroid hormone mechanism of action has derived from investigations of steroid
interaction with normal target tissues such as uterus,
vagina, anterior pituitary, and mammary gland (1).
Jensen and Jacobson (2), as well as Folca et al (3),
initially reported the in vivo uptake and retention of
labeled estrogens by target tissues against concentration gradients.

,,

Jensen and co-workers first succeeded in

synthesizing carrier-free tritiated estradiol 17-beta,
and shortly thereafter demonstrated that•target tissue
localization of estradiol results from the presence of
unique binding components characterized by high affinity
and ligand specificity (.4, 5).

These components have

been designated "estrogen receptors."

An essential char-

acteristic of an estrogen target cell is the ability to
specifically bind estradiol 17-beta with high affinity (1).
Steroid hormone receptors are soluble proteins which
probably play a key role in the mechanism of action of the
steroid hormones (6).

The presence of receptor appears to

be prerequisite for cellular response to changes in
hormonal milieu (7).
1

<

2

Molecular Species
3
By incubation of cytosol with tritiated ( H)
estradiol 17-beta and subsequent sedimentation through a
'

linear gradient of sucrose, specific estrogen binding
components can be identified and characterized, by deter-

mining the distribution of radioactivity in gradient
regions.

Specificity of binding is assured by parallel

incubations with excess unlabeled estradiol or a competitive inhibitor.

The difference in

3

H estradiol bound

-in the presence and absence of inhibitor provides a
''

measure of specific estrogen binding capacity (1).

The

hormone receptor complex of normal breast cytosol sediments at 8-9 S (.Svedbergs) on sucrose gradients of low
salt concentration and a 4-5 Son sucrose gradients of

high salt concentra_tion (8).

Both the 8-9 S and the 4-5

S forms are apparently protein in nature as they are
sensitive to pronase digestion, but insensitive to
nuclease digestion (1).

At physiologic salt concentration

(.15 M) the cytosol hormone receptor complex sediments at
6 S

(9).

The sedimentation profiles of estrogen and progesterone receptors in mammary carcinoma cytosol preparations
fall into four general categories:

migration at 8-9 S,

migration at 4-5 S, migration at both 8-9 Sand 4-5 S,
and undetectable (10, 11).

The presence of the 4 S form

3

in low salt buffers appears to be restricted to
neoplastic tissue, as it has been demonstrated only in
rodent and human mammary carcinoma (12).
Steroid Hormone Mechanism of Action
The series of steps in the interaction of steroid
hormones with their target cells, as currently understood
(see Fig. 1), has evolved from the two step mechanisms proposed independently by Gorski et al (13) and Jensen et al
(14) in 1968.

Steroid hormones are transported in the

plasma by a number of proteins including albumin, sex
steroid binding globulin (SSBG), and corticosteroid
binding globulin (CBG)

(15).

Unbound steroid enters the

cell by passive diffusion and combines with cytoplasmic
receptor in an association characterized by high affinity
and ligand specificity (16).

In the case of estradiol,

it has been proposed that binding occurs onto a 4 S
binding subunit of the 8 S receptor followed by a temperature dependent 4 S to 5 S transformation and subsequent
translocation to the nucleus (6).

The nuclear hormone

receptor complex then associates with chromatin (6);
resulting in stimulation of messenger RNA synthesis and
the subsequent formation of cellular proteins (17, 18).
The nature of the departure and fate of the nuclear
hormone receptor complex is unknown (1).
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Cellular replication and differentiation appear to
result from this cascade of events, when intact (12).
Evidence suggests that the basis for the 4 S to 5 S
transformation is dimerization of the 4 S subunit with
a second·subunit.

Wittliff has proposed that estrogen

receptor of normal breast and responsive tumors consists
of subunits which combine in the presence of estradiol to
form a "6 S" dimer which then translocates to the nucleus.
Chromatin binding i~ vitro is directly proportional
to available estrogen receptor complex, and shows noncompetitive, "unsaturable" behavior.

In one study,

target and non-target muclei in cell free systems bound
3000-4000 molecules of 3 H estradiol receptor complex per
nucleus (19).

The rate of hormone receptor complex

binding to chromatin in vitro is temperature dependent
and incubation of both estrogen receptor complex and
chromatin at 21° C is necessary for significant
association to occur (20).
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Proposed Steps in Steroid Hormone/Target Cell
Interaction. The steroid is designated as S,
the cytoplasmic receptor as Re, and the
nuclear form as Rn. Taken from Wittliff (16).
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Hormone Interactions
Normal breast contains specific binding sites for
estrogens, progestins, corticoids, androgens, prolactin,
growth hormone, and insulin (21).

Estrogen and prolactin

are the two primary hormones in breast growth regulation
(22).

Estrogens and progestins stimulate epithelial cell

differentiation for milk protein synthesis and secretion
(23).

Estrogen also stimulates the release of pituitary

prolactin which is regulatory for alveolar morphogenesis
and mammary gland function (24).

A model of complete

endocrine regulation of breast tissue must include the
interaction of these various hormones (22).
Endocrine Therapy
Surgical interference with endogenous production of
estrogens as palliative therapy for mammary cancer was
first suggested by Sir George Beatson in 1896 in a report
describing the remission of advanced cancer in two women
following bilateral oophorectomy (25).

The biochemical

mechanism of this phenomenon remains incompletely understood (21).

Either removal of endocrine producing

organs or administration of pharmacologic doses of
hormones results in objective remissions in 25-40% of
patients with advanced breast disease (26).
The concept underlying endocrine therapy is that
certain tumor cells retain the ability to respond to the
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same hormonal perturbations as their normal progenitors
( 1) .

That is, certain cancer cells are dependent on o_ne

or more hormones and succumb when deprived of supporting
hormones or when pharmacologic levels of hormone are
administered (26).
Human and experimental breast tumors which regress
following endocrine therapy frequently contain a cytoplasmic protein that specifically binds estradiol with
high affinity (9).

It is assumed that the presence of

estrogen receptor (ER) in breast tumor is due to the
expression of a phenotypic characteristic of the normal,
hormonally responsive cell line of origin (1).

Cells

which have undergone malignant transformation may retain
all or only part of the normal receptor population, and,
in theory at least, hormonal control should be absent in
the absence of specific receptor (26).
The observation, as previously noted, that labeled
estrogens are localized in highest concentrations in
estrogen target organs, led to the suggestion by Jensen
et al that the ability of breast tumor to bind estrogen
might be predictive of responsive to endocrine therapy
(5).

This idea was supported by their later findings in

which the presence of estrogen receptor in tumor biopsies
correlated with favorable response to adrenalectomy (10),
and by the observation of Folca et al that when
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tritiated hexestrol was administered to breast cancer
patients prior to adrenalectomy, metastases which subsequently regressed concentrated a larger fraction of the
labeled estrogen than those which failed to respond (3).
A corre,lation between the presence of estrogen receptor
in breast tumor biopsy material and favorable response to
endocrine therapy was presently confirmed in the laboratories of Wittliff and McGuire (27, 28).
Endocrine additive and ablative therapies are
interventions not without potentially serious complications.

Methods of accurate selection could spare

critically ill patients in whom endocrine therapy is
unlikely to succeed from unnecessary treatment (1).

An

expansion of steroid binding data has followed to the
present, and, while it remains true that estrogen
receptor negative tumors rarely respond to endocrine
therapy, the response of ER positive tumors varies over
a wide range (see Table 1)

(29).

It is now generally

accepted that selection of patients by estrogen receptor
analysis improves the response rate to endocrine therapy
by at least two-fold over non-selected cases (16).

It

has also been suggested that ER negative tumors tend to
have higher mitotic rates as estimated by thymidine
labeling, and that these more rapidly growing tumors
might be expected to respond more favorably to cell cycle
phase specific cytotoxic chemotherapy (30).

9

Table 1.

Relationship Between Estrogen Receptor Status
and Objective Response to Endocrine Therapy.
Taken from Wittliff et al (7).

INVESTIGATOR

ESTROGEN RECEPTOR STATUS
RESPONSES/ER+
RESPONSES/ERTUMORS
TUMORS

Blarney et al

13/30

5/27

Dao and Nemoto

64/119

4/56

DeSombre and Jensen

39/62

4/108

Maass et al

64/93

3/76

Manni et al

68/105

0/12

McCarty~! al

32/58

3/20

Nomura et al

29/45

0/36

Osborne et al

70/145

5/53

Paridaens et al

14/38

0/11

Rubens and Hayward

46/146

5/55

Sing kowinta et al

20/30

2/25

Skinner et al

17/30

5/44

Wittliff

46/76

0/55

522/977 (53%)

36/567(6%)

Specific receptor for progesterone has also been
identified .in breast tumor cytosols (11).

Improved

response rates to endocrine therapy in ER positive tumors
has been reported if specific progesterone receptor (PR)
is also present (See Table 2)

(31),

It has been
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demonstrated that following oophorectomy, cytosol
progesterone receptor levels diminish while cytosol ER
levels remain high (32).

As the synthesis of progeste-

rone receptor may be estrogen dependent the suggestion
has arisen that PR positivity might simply be a reflection
of ER concentration (29).

This concept is complicated by

the puzzling observation that tumors which are ER
negative but PR positive (an enigma in theory) often
respond to endocrine manipulation (See Table 2)

(33).

In any event, it is currently accepted that steroid receptor analysis in mammary carcinoma allows for prediction
of response to endocrine therapy, and that the rate of
response is highest when both ER and PR are present (34).
'Failure to Respond
Many tumors which contain specific estrogen binding
proteins do not respond to endocrine maneuvers.

The

capacity to bind estrogen, therefore, does not obligate
a biological response to the hormone (26).

Events

beyond the level of binding to receptor may be defective,
such as receptor transformation (4 S - 5 S), translocation
to the nucleus, and binding into chromatin (1).
Thus, given the multiple subunit model of lvittliff,
certain unresponsive breast cancers could contain
specific estrogen binding protein, but not the full
complement of receptor subunits necessary for
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transformation and translocation (16).

This may also

explain, at least in part, the improved response rates of
tumors when both ER and PR are present.

The response of

progesterone receptor, assuming the dependence of PR
synthesis on estrogen stimulation, would rule out a defect
in estrogen interaction beyond the level of binding to
receptor (35).

Table 2.

.,

Relationship Between Estrogen and Progesterone
Receptor Status and Objective Response to
Endocrine Therapy.
Taken from Wittliff et al
( 33) .
STEROID. RECEPTOR STATUS

INVESTIGATOR
4/6

2/7

Dao and Nemoto

10/13

18/31

2/28

Degenshein et al.

26/33

3/14

0/14

1/1

King

10/11

3/15

2/9

0/2

McCarty et al

33/40

2/20

3/35

1/3

7/10

8/12

2/20

0/1

Osborne et al

16/20

14/45

3/20

Skinner et al

9/12

2/6

3/30

2/3

2/9
17/165
( 10%)

1/1

Brooks et ·al

Nomura et al

Young ·et al

--

20/29

3/14

135/174
.(.78% l

55/164
(34%)

5/11
( 45%)
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Another factor which may enter into the failure of
receptor positive tumors to respond to endocrine manipulation is the heterogeneity of tumors with regard to
cellular composition.

While the receptor concentration

by assay represents an integrated value for the entire
biopsy, the actual concentration of receptor may vary
widely from cell to cell.

Tumor biopsies which are

receptor (R) positive are likely to include a variable
number of receptor negative cells.

It may be that

hormone dependent cells atrophy as a result of milieu
alterations, while hormone independent cells continue to
proliferate.

This theory is complicated by the obser-

vation that in tumors which regress following
oophorectomy and then resume growth (obstensibly due to
proliferation of the hormone independent sub-population)
a second remission can be induced by further ablative
therapy such as adrenalectomy or hypophysectomy.

A

possible explanation for this phenomenon is that regrowth
included both receptor positive and receptor negative
cells, with peripheral conversion of androstenedione to
estrone allowing R positive cells to participate.
Adrenalectomy or hypophysectomy would eliminate the
adrenal source of estrogen precursors, allowing for the
second regression of R positive cells.

In reality, tumor

cell subpopulations may represent a continuum of varying
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receptor populations in varying concentrations, and different endocrine therapies may be affecting different
levels of endocrine regulation (21).

There is no

apparent correlation between tumor histology and hormone
binding capacity (1, 16, 21).
The pituitary hormone prolactin has also been implicated in experimental mammary tumorogenesis and prolactin
receptor has been demonstrated in membrane fractions of
mammary tumor cells.

It is theorized that prolactin

dependence requires the presence of cell surface

"

receptors (36).

It has been shown that prolactin can

stimulate estrogen receptor in mammary tumors and additionally prolactin may be responsible for progesterone
receptor synthesis- (21). - Physiologic .. amounts _of estrogen
may enhance prolactin receptor levels wherea_s pharmacologic doses of estrogen may reduce receptor levels as
an antagonist at the tissue level (24).

It has been

reported that elevation of serum prolactin results in an
increase in the size and number of dimethybenz(a) anthracene (DMBA) induced mammary carcinomas, and can
reactivate tumor growth following oophorectomy, adrenalectomy and hypophysectomy (37).

Further, reduction of

serum prolactin results in inhibition of growth of
spontaneous and DMBA induced rat mammary tumors (38).
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Prolactin also participates in the development and
progression of some human mammary cancer, but the relationship is poorly understood, and human tumors may be
less sensitive to prolactin than experimental tumors
(39).

However, prolactin dependency may explain why 20%

of estrogen receptor and progesterone receptor positive
tumors fail to respond to endocrine therapy (40).
The relationship between receptor level and biological response is complicated and unless receptor concentration is rate limiting, significant differences in
receptoreceptor level may occur without significant
differences in hormone response (24).

Prediction of

hormone dependency by steroid receptor status may be
something of an oversimplification, but loss of receptor
may at least be viewed as indicative of departure from
normality (9).
Titration Analysis
Sucrose gradient centrifugation (as previously
described) and titration assay are generally recognized
as the most acceptable methods of receptor analysis
(33).

In titration analysis, tissue preparations are

equilibrated with increasing quantities of radioactive
hormone, where, under appropriate conditions of pH and
temperature, the radiolabeled hormone combines with
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receptor, if present, and forms the hormone receptor
complex (16).
Estimations of receptor affinity and binding site
concentrations require separation of bound from free
hormone.

A number of techniques have been employed for

this purpose including electrophoresis, chromatography,
dextran coated charcoal (DCC) adsorption of free steroid,
protamine sulfate protein precipitation, and protein
adsorption to hydroxylapatite (41).
Hydroxylapatite [3Ca (P0 )
. Ca(OH) J is a
2
3
4 2
homogenous insoluble chemical which can be obtained in
analytical grade quantities of uniform particle size,
and which can readily be pelleted or resuspended.

The

hydroxylapatite technique involves adsorption of protein
bound tritiated hormone onto hydroxylapatite particles,
separation from the liquid phase by centrifugation,
sequential washes with buffer to remove residual unbound
hormone, extraction of tritiated hormone adsorbed to
hydroxylapatite pellet into ethanol, and quantitation of
bound activity by scintillation counting.

Hormone

receptor adsorption to hydroxylapatite appears to be unaffected by increasing ionic strength up to 2.5 Mand is
therefore of value in quantitating nuclear hormone receptor complex as well, which is generally defined as
extractable in buffer containing .3 -

.6 M KCl (41).

16

Additionally, hydroxylapatite shows little affinity for
free steroid, adsorption can be carried out at O - 2° C,
and the hydroxylapatite method is more accurate than
the DCC method at low protein concentrations (42).
Most tissue preparations contain, in addition to
specific high affinity receptors, other low affinity, high
capacity, "non-specific" binding components such as plasma
contaminants (43).

Estimations of receptor parameters

rely on separation of, or correction for, binding to
non-specific components and the use of equations based on
the law of mass action for the interaction of the steroid
(S) and a single class of receptor (R) given by:
S + R

:::;;:= S • R

(44).

The widely used method of

correction for non-specific binding involves equilibration
of tissue preparations with increasing concentrations of
radioactive steroid, and in parallel incubations specific
binding is inhibited by addition of radioinert ligand or
competitive inhibitor.

Specific binding can be deter-

mined by the difference between total bound activity in
the absence of competitor and the amount of non-specific
binding which occurs in the presence of excess competitor
(45l •

In routine steroid receptor assay, many laboratories
present their results in the form of a Scatchard plot
(46), where the x-variable is B

s

and they - variable is
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Bs / F

BT - BNS = BS, where BT is total bound

(47).

activity in the absence of competitor, BNS is activity
bound "non-specifically'' in the presence of excess competitor, and BS is specifically bound activity (44, 47).
For methods which estimate the bound moiety (such as the
hydroxylapatite method) the unbound or free moiety (Fl is
estimated by subtracting total bound from total ligand
present, or:

T -

B

T

=F

( 4 3) •

After plotting points obtained from several concentrations, a straight line is fitted, least squares
regression analysis being the usual formal method (47).
For points on the graph described by (X
(X

n

is:

1

, Y ) {X , Y l···
1
2
2

, Y ), the equation of the line fitted to such points
n

y

=

mx + b; where mis the slope of the line and b

is the Y intercept.

For least squares regression analysis

the estimate of the slope, m, is given by:

m

=

l: {x 1

°2

-

X)

(Y

(Xl -

-

1

Y)
(48).

The intercept of the line

X) 2

with the ordinate, b, is given by:

b

= Y-

m X.

The

intercept of the line with the abscissa, Bmax' can then
be calculated by:
max =

B

b
m

{ 4 8) •

Y

=

m x + b; setting Y

=

0:

As long as Bis used with the same

units for plotting both BS and BS/ F, a valid plot
results whose B intercept (Bmax) is an estimate of
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binding site concentration and whose slope is - 1/Kd,
where Kd is the dissociation constant of the hormone receptor complex (45).
In a system with two descrete levels of specific
activity, binding parameters can be calculated in terms of
count rates and converted to molar concentrations for
final binding parameters (43).

Binding capacity is
-15
usually expressed as femptomoles (10
M) of binding
sites per milligram of cytosol protein (49).
Sources of Error
Titration analysis measures only unoccupied receptor.
Theoretically only tissues with small receptor concentrations should be affected by receptor occupancy by
endogenous hormone, but under some circumstances substantial dilution of radioactive steroid by dissociation
of endogenous hormone from high capacity non-specific
components during equilibration may distort estimates of
receptor parameters.

Also, some steroids are readily

adsorbed to glass or plastic surfaces.

Since either the

bound or the unbound fraction is estimated by the difference between the total steroid added and the moiety
quantitated, systematic errors can arise if steroid is
lost by adsorption.

Overestimates of bound steroid

result in over estimates of binding site concentration
and underestimates of Kd, whereas overestimates of

19

unbound· steroid result in overestimates of Kd, but do not
affect binding site estimates (43).

When excess radio-

inert ligand is used to correct for non-specific binding,
a problem can arise at high ligand concentrations, where
competition can occur for binding components of relatively
low affinity (45).
Carcinogen_esis
It is established that the mammary gland is sensitive
to the actions of carcinogens and is a major site for the
concentration of dimethylbenz(a)-anthracene (DMBA) and
trimethylbenz(a) anthracene (TMBA)

(50).

Both 7,12 DMBA

and 7,8,12 TMBA are highly carcinogenic, characterized by
multiplicity of tumors and rapidity of carcinogenesis.
Carcinogenicity of aromatic hydrocarbons is associated
with their ability to form charge transfer complexes with
local acceptors and donate an electron.

There is· also a

direct increase in carcinogenicity as hydrocarbons become
sterically similar to steroids.

There is a remarkable

steric similarity between carcinogenic polynuclear
aromatic hydrocarbons, growth promoting steroids, and
nucleic acid base pairs.

Based on experimental data,

Huggins made the following proposition:

"Every 50 day

old, intact, female rat of the Sprague-Dawley strain fed
a single meal of 20 mg 7,12 DMBA in oil emulsion will
develop mammary adenocarcinoma"

(51).
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Specific receptors for estrogen, progesterone, and
prolactin have been demonstrated in DMBA induced tumors
(38, 52).

Receptor of DMBA induced tumors behaves like

that of human mammary tumors with regard to range of
concentrations, affinity (Kd), and molecular species by
gradient centrifugation (21).

It has been reported that

among tumors induced by DMBA in rats of the Sprague-Dawley
strain, 85-90% are estrogen receptor positive and 85% are
progesterone receptor positive (53) 60% of DMBA tumors
are prolactin dependent (54).
DMBA induced carcinoma of the rat shares a number of
characteristics with human breast cancer, as well as some
differences.

The common characteristics in biological

behavior and response of cytostatic and endocrine therapy
make chemically induced rat mammary carcinoma a suitable
model for human breast cancer (55).

In this investiga-

tion, cytoplasmic and nuclear binding sites for estrogen
and progesterone in DMBA induced mammary carcinomas were
analyzed by titration assay.

Results were compared

between two groups of tumors categorized by response to
oophorectomy.

In one group, termed hormone dependent,

tumors regressed completely following oophorectomy.

In

the second group, termed hormone independent, tumors
continued to grow.

It is the purpose of this study to
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examine the differences in steroid binding parameters
between these two biologically defined tumor populations:

MATERIALS AND METHODS
Animal Treatment
Immature female rats of the Sprague-Dawley strain
were obtained from Harlan Industries, Indianapolis, Ind.,
housed in temperature- and light-controlled quarters, and
supplied with water and Purina Laboratory Chow (Ralston
Purina Co., St. Louis, Mo.) ad libitum.
At age 50 ± 1 days, under light ether anesthesia,
animals were administered a single feeding of 20 milligrams of 7,12 dimethylbenz(a) anthracene (DMBA), in 2
milliliters of oil emulsion, by intra-gastric
instillation.
Beginning at one month after DMBA treatment, animals
were palpated once a week for the appearance of mammary
tumors.

When the average diameter of a palpable tumor

exceeded 2 cm., the animal was anesthetized with
pentabarbital (the Butler Co., Columbus, 0.) at a dose
of 3 - 4 mg per 100 g body weight intraperitoneally, and
subjected to bilateral oophorectomy.

At the time of

surgery, tumors were measured with calipers and mapped.
Approximately 1/2 of the tumor was removed for receptor
analysis, leaving 1/2 part in the host for observation
of .its growth pattern.
Tumor biopsies were dissected free of connective
22
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tissue and debris, frozen on dry ice/acetone and stored
at -20° C.
Hormone Dependence
If following oophorectomy, a tumor regressed
completely it was termed hormone-dependent, and if it
continued to grow it was termed hormone-independent, the
period of observation being one month.

For the hormone

dependent group, biopsy material obtained at oophorectomy
was utilized for receptor analysis.

For the hormone

independent group, animals bearing tumors which continued
to grow following oophorectomy were stunned and decapitated and tumor tissue was removed and processed as
described for tissues obtained at oophorectomy.
Reagents
3
For binding experiments [2,3,4,5,16,17- HJ estradiol
- 17 beta (151 ci/mmol),

[17 oc methyl -

3
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R5020 (17,21

dimethyl-19-nor-4,9-pregnadiene-3,10-dione; 85 ci/mmol),
and radioinert R5020 were obtained from New England
Nuclear Corp.

Unlabeled diethylstibestrol (DES), Tris

preset crystals (pH 7. O at 27° Cl, a.nd n,n-dimethyl
formamide were purchased from Sigma Chemical Co.
ScintiVerse E was purchased from Fischer Scientific, and
Analytical grade hydroxylapatite (DNA grade BioGel HTP)
was purchased from BioRad.
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Determination of Cytosol and Nuclear Binding Sites
Binding site determinations employed and modifications of the hydroxylapatite methods of Chamness et al
and Pavlik and Coulson (41, 57).

All procedures were

carried out on ice or refrigerated at O - 4° C, unless
otherwise specified.
Frozen tissue was weighed, minced on a cold glass
plate and homogenized in buffer containing 10 rnM Tris
0

(pH 7.56 at O) and 7 1/2 percent n,n dimethylformamide
(v/v).

Homogenizations were carried out in a seven

milliliter TenBroeck pyrex glass-glass tissue grinder
at a ratio of approximately 100 mg tissue per ml buffer.
The homogenate was centrifuged 10 minutes at 800 x g.
The supernatant was further centrifuged for 50 minutes
at 45,000 x g to yield the high speed supernatant
(cytosol).

The first pellet was resuspended in homo-

genization buffer and washed twice by centrifugation for
10 minutes at 800 x g discarding the supernatants, then
resuspended for one hour in homogenization buffer containing 0.4 M potassium chloride for extraction of
nuclear receptors.

The pellet suspension was then

centrifuged for 10 minutes at 3000 x g .and the supernatant

(nuclear extract) was assayed for nuclear

receptors.
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Five hundred microliter aliquots of cytosol or
nuclear extract were incubated with four final concen3
trations of either [ H] estradiol - 17 Beta (.15,

.5,

3.0, 10.0 nM) or [ 3 HJ R5020 (.5, 3.0, 15.0, 45 nM) in
homogenization buffer.

Reactions were performed in

parallel with a 200 - fold excess of radioinert competitor for determination of non-specific binding.

DES

was used in estrogen receptor assays and unlabeled
R5020 was used in progesterone receptor assays.
Incubations were for 16-18 hours at O - 4° C.

The

synthetic progestin R5020 is especially useful in
receptor studies because it does not bi"nd to corticosteroid binding globulin (CBG)

(11).

Similarly, an

important advantage of DES (a non-steroidal estrogen) is
its low affinity for sex steroid binding globulin (SSBG)
( 4 9) •

Hydroxylapatite (HAP)
At the end of incubation duplicate 200 microliter
aliquots from each incubation tube were added to tubes
containing one milliliter of 10% hydroxylapatite slurry
(prepared by suspending 10 grams of DNA grade BioGel HTP
in 100 ml of homogenization buffer).

Adsorption to HAP

was carried out for 45 minutes, ~ith occasional vortex
mixing to maintain suspension.

The HAP was then pelleted

by centrifugation for 2 minutes at 800 x g.

The pellet
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was washed three times with 2 ml homogenization buffer
by centrifugation for 2 minutes at 800 x g, discarding
the supernatants.
liound radioactive steroid was removed from HTP by
extraction into 1.5 ml lOOi ethanol (30 minutes, room
temperature), and then counted in 5 ml of scintillation
fluid (ScintiVerse E, Fischer Scientific).

All counts

W<>re made in Packard TriCarb Model 300 Liquid
Scintillation Spectrometer at Maxey Flats Low-Level
Nuclear Waste Disposal Site.
For the calculation of binding capacity (B

max

) and

affinity (dissociation constant, Kd), daia were plotted
according to the method of Scatchard (46) and subjected
to least squares regression analysis.

Table 3 and

Figure 2 depict representative titration data and
Scatchard analysis.

Total bound steroid (BT) is the

amount of radioactive steroid bound in the absence of
competitor.

Non-specifically bound steroid (BNS)

represents the amount of tritiated steroid bound in the
presence of a 200-fold excess of radioinert competitor.
Total radioactive steroid (Tl was estimated by direct
sampling of incubates prior to the addition of the
hydroxylapatite slurry.

The quantities of BT, BNS' and

T were determined by scintillation counting while
specifically bound steroid (BS) was estimated by
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subtracting BNS from BT, and total free steroid (F) was
estimated by subtracting BT from T.

Specifically bound

steroid (BS), as the x-variable, was plotted against the
bound to free ratio (Bs/F) as they-variable (Figure 2).
A line was fitted to the data points by least squares
regression analysis and B
and Kd were estimated as
max
the x-intercept and - 1/slope, respectively.

Bmax and

Kd were calculated in terms of count rates (disintegrations per minute, dpm) and then converted to molar
concentrations.

Estimated binding sites (the molar

equivalent of B
) were standardized by protein concenmax
tration, as determined by the method of Lowry et al ( 56),
with bovine serum albumin (1 mg/ml) as standard.

The

data were expressed as femptomoles of bound steroid per
milligram of protein (fmol/mg) for estimated binding
sites and moles per liter (Ml for Kd.

Table 3.

3
Representative Titration Data (Cytosolic H Estradiol Binding,
Tumor Number 5) In Disintegrations Per Minute (dpm).
BT= total bound, BNS = non-specifically bound, Bs = specifically
bound (BT - BNS = Bs), T = total radioactive steroid added, and
F = total free steroid (T - BT= F).
3H Estradiol Concentration

T

F

B /F
s

11,448

656,300

590,161

.019

10.0 nM

19,115

11,420

189,811

159,276

.072

3.0 nM

11,529

3,819

7,710

45,500

33,971

.227

. 5 nM

1,578

472

1,106

4,639

3,061

.361

.05 nM

BNS

B

66,139

54,691

30,535

BT

s

N

00
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0. 4 -

Bs/F

0.2

0.1

4

8

12

16

BS (dpm x 10-3)

Fig1Jre 2.

Representative Scatchard Plot (cytosolic
estrogen binding, tumor number 5).
Bs
(specifically bound} is plotted against
Bs/F (bound to free ratio). A line was
fitted by least squares regression. Gmp disintegrations per minute.

RESULTS AND DISCUSSION

Estrogen and progesterone binding sites in tumor
cytosol and nuclear extract were analyzed by multiple
point titration assay for a total of eight tumors.
Estimates of binding site concentration and dissocation
constant (Kd) are summarized in Table 4.
Analysis of estro~en receptors (ER) shows that 88%
of tumors are positive for cytosol binding sites, 63%
are positive for nuclear binding sites, and 50% are
positive for both.

Analysis of progesterone receptors

(PR) shows that 50% are positive for cytosol binding
sites and 50% are oositive for nuclear binding sites,
while only one tumor is positive for both (tumor number
3) •

Estimates of dissociation constants of dissociation
3
constants of 3 H estradiol = 17 beta or H R5020 from
their receptors indicate high affinity binding sites.
Tumors from both groups (hormone-dependent and hormoneindependent) contained estrogen-receptor complexes with
Kd values of

CJ'\

Kd values of

Cll

l0- 9 M, and R5020-receptor complexes with
10-sM.

No significant differences were

observed in the affinities of either of these binding
sites between groups (Table 5), indicating that differences in biological response were not correlated with
30

Table 4.

Tumor
Number

Binding Data. Estimates Of Binding Site Concentrations (Expressed As
Femptomoles Per Milligram Of Protein) and Kd (in parentheses).
3

cytosol

1

18.9
(. 82xlo-9M)

2

10.8
(2.6xio- 9 M)

nuclear

0

0

4

5

(A)65.5
(. 48xio-9M)

19.7
(.17x10-9N)

6

1.0
( .18xl0-9M

(B)71.8
(2.lxlo-9M)

8

Percent Receptor
Positive
88%

R5020

0

215.0
(3.8x10-8M)
0

(C) 853.1
(2.4xl0-8M)
0

80.0
(. 88x10-8r~)

0

16.6
(. 32xio-9M)

n

cytosol
147.0
(. 7 5x10-8i1)

7.2
(.5xl0-9M)

3

7

3

n estradiol - 17 /3

0

63%

0

50%

nuclear

Biological
Behavior

0

independent

85.6
(.46xlo- 8 M)

independent

87.6
(. 56xl0-8M)
59.3
(2.3xl0-8M)

dependent

independent

0

dependent

O

dependent

O

independent

(D)468.9
( 1. 4x10-BM)
50%

dependent
w

f-'
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Table 5.

Average Dissociation Constant (Kd) Expressed
F,s Moles/liter (M) •

Group

Hormone
Dependent
Hormone
Independent
All

3

H estradiol - 17~

-9

3H

R5020

2.0 X 10 -8 M

.59

X

10

1. 29

X

10- 9 M

1.0

X

10- 8 M

.88

X

10- 9 M

1.6

X

10- 8 M

M
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alterations in the association action between the steroid
and its receptor.
Tables 6, 7, and 8 correlate all distributions of
receptor occurring in the data set with response to
oophorectomy.

For groups containing more than one tumor,

receptor status correlates most closely with regression
when estrogen receptor is present in both the cytosol and
nuclear extract or when both estrogen and progesterone
receptor are present in the cytosol (75% and 67% regressed,
respectively; A, tables 6 and 8).

The one tumor con -

taining cytosolic and nuclear binding sites for both
estrogen and progesterone (B, table 8) was hormone
deoendent,
in vivo.
..
-

Likewise, the absence of either

cytosolic or nuclear estrogen receptor is associated with
diminished regression rate in response to oophorectomy
(0 and 33%; Band C, table 6).

While considered by

itself, the presence or absence of progesterone receptor
is not distinguished by response to oophorectomy, the
presence of cytosol progesterone receptor when estrogen
receptor is also positive correlates with increased
numbers of regressions.
It should be noted that one tumor positive for both
cytosolic and nuclear estrogen receptor,

(D, table 6)

and one tumor with cytosol positive for both estrogen and
progesterone receptor,

(C, table 8)

was

hormone
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Table 6.

Estrogen Receptor (ER) Distribution and
Response to Oophorectomy.

Receptor Status
Cytosol
Nuclear

Total Number
of Tumors

Number of
Regressed
Tumors

ER+

7

4

ER-

1

( B) 0

ER+

5

3

(60%)

2

ER-

3

(Cl 1

(33%)

2

ER+

ER+

4

(A) 3

(75%)

(D)l

ER+

ER-

3

1

(33%)

2

ER-

ER+

1

0

Table 7.

(57%)

Number of
Growing
Tumors
3

1

1

Progesterone Receptor (PR) Distribution and
Response to Oophorectomy.

Receptor Status
Nuclear
Cytosol

Total Number
of Tumors

Number of
Regressed
Tumors

Number of
Growing
Tumors

PR+

4

2

(50%)

2

PR-

4

2

( 50%)

2

PR+

4

2

( 50 %)

2

PR-

4

2

( 5 0%)

2

PR+

PR+

1

1

(100%)

0

PR+

PR-

3

1

(33,%)

2

PR-

PR+

3

1

(33%)

2

PR-

PR+

1

(A) 1

(100%)

0
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Table 8.

Distribution and Response To Oophorectomy.
Estrogen and Progesterone Receptor.

Receptor Status
Cytosol

Nuclear

Total Number
of Tumors

Number of
Regressed
Tumors

Number of
Growing
Tumors

ER+PR+

3

(A) 2

(67%)

(C)l

ER+PR-

4

2

( 50%)

2

ER-PR+

1

0

ER+PR+

1

1

(100%)

0

ER+PR-

4

2

( 5 0 %)

2

ER-PR+

3

1

( 3 3%)

2

ER+PR+

ER+PR+

1

ER+PR+

ER+PR+

2

1

(50%)

1

ER+PR-

ER+PR-

1

1

(100%)

0

ER+PR-

ER-PR+

3

ER-PR+

ER+PR-

1

1

(B)l (100%)

(D)l (33%)
0

0

2

1
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independent in vivo.

Also, one tumor which was negative

for progesterone receptors, both cytosolic and nuclear,
(A, table 7) and one tumor which was negative for nuclear
estrogen receptor and cytosolic progesterone receptor,
(D, table 8) were hormone-dependent in vivo.

It has been

shown that prolactin can stimulate estrogen receptor ,in
mammary tumors (58) and it is unknown whether progestin
receptors are dependent on estrogen action directly or
estrogen induced prolactin secretion (59).

The presence

of prolactin binding in the absence of estrogen binding

,,

can be associated with autonomous growth (22).

Prolactin

dependence may explain the presence of ER and PR in these
"hormone-independent" tumors, and conversely, sensitivity
to alterations in prolactin concentration may be responsible for regression of the two tumors with minimal estrogen and progesterone receptor populations.

The same

model of prolactin dependence can account for the regression of tumors which are steroid receptor negative and
the continued growth of steroid receptor positive tumors
following oophorectomy.
Mean receptor concentration was higher for both
hormones in both locations, cytosol and nuclear extract,
in the hormone dependent group (Table 9).

Differences

between groups did not attain statistical significance.
Inspection of the binding data indicates that mean binding

Table 9.

Average Receptor Concentration Expressed As Femptomoles Per Milligram
Of Protein (Mean~ Standard Deviation).
3

Group

H estradiol-17
cytosol
nuclear

Hormone
Dependent

23.6 + 28.6

Hormone
Independent

12.2 +

9.0

8.1 + 14.7

All

17.9 + 20.6

16.4 + 24.9

24.7 + 32.5

3H
cytosol

267.0 + 403.7
56.8 +

71.0

161.9 + 290.9

R5020
nuclear

139.1 + 223.7
36.2 +

43.2

87.7 + 158.9

w
....,
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site concentrations in the hormone dependent group are
shifted upward by the pr•,•sence in each hormone receptor
location of one tumor with a binding capacity several
fold larger than the rest,

(A,B,C,D; Table 4).

The

observation that very high binding capacity in each case
is associated with hormone independence is particularly
interesting in light of the suggestion by several
investigators that hormone dependency among breast
tumors may represent a continuous function of receptor
concentration (29).

SUMMARY

Normal breast tissue contains specific binding sites
for each of the hormones known to influence its growth or
development.

With malignant transformation, cells may

retain all or only part of the normal population of
receptor sites.

If a cell retains receptors, it remains

at least potentially capable of being regulated by the
hormonal environment.

If receptor sites are lost, the

cell may escape from endocrine control (22).
The results of this investigation suggest a correlation between increasing estrogen and progesterone
receptor populations in the qualitative sense and
increasing numbers of regressions in response to
oophorectomy, and perhaps a quantitative relationship
between steroid receptor concentration and hormonedependence in vivo.

The relationship between inter-

mediate receptor populations and intermediate binding
capacities is unreliable however, and suggests the need
for evaluation of binding parameters for other hormones
influencing breast growth and function, particularly
prolactin, for a more complete understanding of hormone
responsiveness.
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